$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000112623415000189 Filed on November 06, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q4
Revenue	$7.652M	$14.21M	$169.2M
YoY Change	-95.48%	407.28%	57466.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.700M	$7.400M	$8.300M
YoY Change	-7.23%	51.02%	176.67%
% of Gross Profit
Research & Development	$14.80M	$22.51M	$11.90M
YoY Change	24.37%	106.57%	128.85%
% of Gross Profit
Depreciation & Amortization	$500.0K	$500.0K	$300.0K
YoY Change	66.67%	66.67%	0.0%
% of Gross Profit
Operating Expenses	$22.50M	$29.89M	$20.20M
YoY Change	11.39%	88.87%	146.34%
Operating Profit	-$14.83M	-$15.68M	$149.0M
YoY Change	-109.95%	20.4%	-1983.36%
Interest Expense	$0.00	$88.00K	$0.00
YoY Change
% of Operating Profit			0.0%
Other Income/Expense, Net	$0.00	-$63.00K	$0.00
YoY Change		-520.0%
Pretax Income	-$14.80M	-$15.75M	$149.0M
YoY Change	-109.93%	21.02%	-1986.08%
Income Tax	$6.700M	$160.0K	$29.00M
% Of Pretax Income			19.46%
Net Earnings	-$21.57M	-$15.91M	$120.0M
YoY Change	-117.98%	184.14%	-1591.6%
Net Earnings / Revenue	-281.94%	-111.94%	70.91%
Basic Earnings Per Share	-$0.75	-$0.55	$4.29
Diluted Earnings Per Share	-$0.75	-$0.55	$3.83
COMMON SHARES
Basic Shares Outstanding	28.79M shares	28.73M shares	27.96M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$197.8M	$200.4M	$202.8M
YoY Change	-2.47%	196.01%	229.76%
Cash & Equivalents	$195.6M	$197.1M	$190.4M
Short-Term Investments	$2.200M	$3.200M	$12.40M
Other Short-Term Assets	$5.000M	$1.800M	$8.300M
YoY Change	-39.76%	350.0%	937.5%
Inventory
Prepaid Expenses	$4.954M	$1.768M	$8.333M
Receivables
Other Receivables
Total Short-Term Assets	$208.1M	$217.2M	$223.6M
YoY Change	-6.92%	175.76%	249.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.40M	$9.628M	$7.599M
YoY Change	36.86%	35.28%	15.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$10.40M	$9.628M	$7.599M
YoY Change	36.86%	35.28%	15.36%
TOTAL ASSETS
Total Short-Term Assets	$208.1M	$217.2M	$223.6M
Total Long-Term Assets	$10.40M	$9.628M	$7.599M
Total Assets	$218.5M	$226.8M	$231.2M
YoY Change	-5.48%	164.12%	227.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.661M	$1.494M	$2.412M
YoY Change	51.78%	-49.1%	294.12%
Accrued Expenses	$8.761M	$8.155M	$9.367M
YoY Change	-6.47%	102.56%	227.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$558.0K	$558.0K	$157.0K
YoY Change	255.41%	189.12%	1.95%
Total Short-Term Liabilities	$14.84M	$11.22M	$25.02M
YoY Change	-40.69%	54.95%	545.54%
LONG-TERM LIABILITIES
Long-Term Debt	$368.0K	$409.0K	$941.0K
YoY Change	-60.89%	-58.65%	-8.91%
Other Long-Term Liabilities	$7.600M	$7.800M	$8.300M
YoY Change	-8.43%	6.85%	13.7%
Total Long-Term Liabilities	$7.928M	$8.192M	$9.264M
YoY Change	-14.42%	-0.68%	10.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.84M	$11.22M	$25.02M
Total Long-Term Liabilities	$7.928M	$8.192M	$9.264M
Total Liabilities	$22.77M	$19.41M	$34.29M
YoY Change	-33.59%	25.32%	180.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$80.35M	-$58.78M	-$39.96M
YoY Change	101.08%	-63.26%	-70.61%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$771.0K	$551.0K	$222.0K
YoY Change	247.3%	148.2%
Treasury Stock Shares	24.03K shares	17.80K shares	10.39K shares
Shareholders Equity	$195.8M	$207.4M	$196.9M
YoY Change
Total Liabilities & Shareholders Equity	$218.5M	$226.8M	$231.2M
YoY Change	-5.48%	164.12%	227.71%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q4
OPERATING ACTIVITIES
Net Income	-$21.57M	-$15.91M	$120.0M
YoY Change	-117.98%	184.14%	-1591.6%
Depreciation, Depletion And Amortization	$500.0K	$500.0K	$300.0K
YoY Change	66.67%	66.67%	0.0%
Cash From Operating Activities	-$8.400M	-$7.000M	$130.7M
YoY Change	-106.43%	-17.65%	-1733.75%
INVESTING ACTIVITIES
Capital Expenditures	-$500.0K	-$1.300M	-$400.0K
YoY Change	25.0%	30.0%	300.0%
Acquisitions
YoY Change
Other Investing Activities	$1.000M	$1.000M	$4.300M
YoY Change	-76.74%	-106.1%	-1533.33%
Cash From Investing Activities	$500.0K	-$300.0K	$3.900M
YoY Change	-87.18%	-98.28%	-1400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.400M	1.000M	4.800M
YoY Change	33.33%	900.0%	-72.88%
NET CHANGE
Cash From Operating Activities	-8.400M	-7.000M	130.7M
Cash From Investing Activities	500.0K	-300.0K	3.900M
Cash From Financing Activities	6.400M	1.000M	4.800M
Net Change In Cash	-1.500M	-6.300M	139.4M
YoY Change	-101.08%	-75.58%	1382.98%
FREE CASH FLOW
Cash From Operating Activities	-$8.400M	-$7.000M	$130.7M
Capital Expenditures	-$500.0K	-$1.300M	-$400.0K
Free Cash Flow	-$7.900M	-$5.700M	$131.1M
YoY Change	-106.03%	-24.0%	-1759.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	222000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4808000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3489000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28785448	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
	nlnk	Allocated Accellerationof Sharebased Compensation Expense AllocatedAccellerationofSharebasedCompensationExpense	2400000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	8687000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	341000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2014Q4	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	190404000	USD
CY2015Q3	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	197141000	USD
CY2014Q4	nlnk	Contractmanufacturingorganizationequipment Contractmanufacturingorganizationequipment	1023000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6737000	USD
CY2015Q3	nlnk	Contractmanufacturingorganizationequipment Contractmanufacturingorganizationequipment	1075000	USD
CY2015Q3	nlnk	Genentech Potential Milestones GenentechPotentialMilestones	1000000000	USD
CY2015Q3	nlnk	Genentech Revenue Recognized GenentechRevenueRecognized	808000	USD
	nlnk	Genentech Revenue Recognized GenentechRevenueRecognized	14400000	USD
CY2014	nlnk	Genentech Upfront Payments GenentechUpfrontPayments	150000000	USD
	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	150000	USD
	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	459000	USD
CY2014Q4	nlnk	Lab Equipment LabEquipment	4110000	USD
CY2015Q3	nlnk	Lab Equipment LabEquipment	5168000	USD
	nlnk	Merck One Time Milestones MerckOneTimeMilestones	20000000	USD
CY2015Q3	nlnk	Merck Revenue Recognized MerckRevenueRecognized	36000	USD
	nlnk	Merck Revenue Recognized MerckRevenueRecognized	170000	USD
CY2014	nlnk	Merck Upfront Payments MerckUpfrontPayments	30000000	USD
CY2014Q4	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2015Q3	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2014Q4	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	13000	USD
CY2015Q3	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	472000	USD
CY2014Q4	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	12554000	USD
CY2015Q3	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	15654000	USD
CY2014Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3716000	USD
CY2015Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	14518000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2412000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1494000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9367000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8155000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4955000	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6026000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	236838000	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	266454000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3300000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6900000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3300000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12400000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4889027	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5790468	shares
CY2014Q4	us-gaap	Assets Assets	231221000	USD
CY2015Q3	us-gaap	Assets Assets	226819000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	223622000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	217191000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	350000	USD
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	35000	USD
CY2015Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	22000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61291000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51070000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1344000	USD
CY2014Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	12393000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	160000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	143000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190404000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	197141000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10221000	USD
CY2015Q3	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	3216000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27991242	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28792711	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27980849	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28774911	shares
CY2014Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	280000	USD
CY2015Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	288000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2015Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	85000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1238000	USD
CY2015Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1175000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12966000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	901000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1085000	USD
CY2015Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	608000	USD
CY2015Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9300000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14500000	USD
CY2015Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19800000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	814000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1071000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.86
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2015Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-9177000	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4931000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11044000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7384000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23007000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-13011000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-31410000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-15746000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-18807000	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7413000	USD
CY2014Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	8763000	USD
CY2015Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	76000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7413000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	62000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	62000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1780000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-7632000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3450000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12542000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1392000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	10802000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-420000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-6565000	USD
CY2014Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	5000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	18000	USD
CY2015Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	88000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	98000	USD
	us-gaap	Interest Paid InterestPaid	18000	USD
	us-gaap	Interest Paid InterestPaid	37000	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	20000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	65000	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	25000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	68000	USD
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	6022000	USD
CY2015Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7086000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	34285000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	19407000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	231221000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226819000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25021000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11215000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9264000	USD
CY2015Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8192000	USD
CY2014Q3	us-gaap	Licenses Revenue LicensesRevenue	0	USD
	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2015Q3	us-gaap	Licenses Revenue LicensesRevenue	844000	USD
	us-gaap	Licenses Revenue LicensesRevenue	34555000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	157000	USD
CY2015Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	558000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	941000	USD
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	409000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29119000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16745000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17731000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5727000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-21609000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15735000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	15827000	USD
	us-gaap	Operating Expenses OperatingExpenses	34804000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	29892000	USD
	us-gaap	Operating Expenses OperatingExpenses	79626000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13026000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-31457000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15683000	USD
CY2015Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1900000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18777000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	47000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-30000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	16387000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2015Q3	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8333000	USD
CY2015Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1768000	USD
	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	6800000	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	13500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29382000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17230000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	97000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2014Q3	us-gaap	Profit Loss ProfitLoss	-5598000	USD
	us-gaap	Profit Loss ProfitLoss	-23997000	USD
CY2015Q3	us-gaap	Profit Loss ProfitLoss	-15906000	USD
	us-gaap	Profit Loss ProfitLoss	-18807000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1399000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2325000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7599000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9628000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	23000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	27000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	115000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	117000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10896000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23760000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22508000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56619000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39960000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58779000	USD
CY2014Q3	us-gaap	Revenue From Grants RevenueFromGrants	2801000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	3347000	USD
CY2015Q3	us-gaap	Revenue From Grants RevenueFromGrants	13365000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	26294000	USD
CY2014Q3	us-gaap	Revenues Revenues	2801000	USD
	us-gaap	Revenues Revenues	3347000	USD
CY2015Q3	us-gaap	Revenues Revenues	14209000	USD
	us-gaap	Revenues Revenues	60849000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6901000	USD
	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan	18988	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	453079	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	329402	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	12394000	USD
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	USD
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	7949	shares
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	341000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	196936000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13534000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12394000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3295000	USD
CY2015Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	207412000	USD
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	10393	shares
CY2015Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	17800	shares
	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	542	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	222000	USD
CY2015Q3	us-gaap	Treasury Stock Value TreasuryStockValue	551000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27914782	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27800246	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28734768	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28518503	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">escription of Business</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for cancer and other diseases. NewLink initiated operations in April 2000.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2005, NewLink created a partially owned subsidiary, BioProtection Systems Corporation (BPS). NewLink contributed certain licensing agreements and other intangible assets for BPS to create vaccines against potential biological terror threats. On January 7, 2011, NewLink acquired all of the minority interest in BPS by merging a newly formed subsidiary of NewLink with BPS, with BPS as the surviving corporation, resulting in NewLink owning all the outstanding capital stock of BPS. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, NewLink created a wholly-owned subsidiary, NewLink International (NI). NewLink plans to conduct all or a portion of its operations outside of the United States through NI. In 2014, NewLink created another wholly owned subsidiary, NewLink Global (NG), which was subsequently merged into NewLink during 2014.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company had a net loss of </font><font style="font-family:inherit;font-size:10pt;">$15.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$18.8 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ending</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying financial statements as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months then ended</font><font style="font-family:inherit;font-size:10pt;"> have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from the ATM Offering prior to </font><font style="font-family:inherit;font-size:10pt;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;">. In connection with two license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck, Sharpe and Dohme Corp., or Merck, in 2014, as well as an additional milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in February 2015. The Company's cash and cash equivalents after these agreements and offerings are expected to be adequate to satisfy the Company's liquidity requirements through 2016, although not through commercialization and launch of revenue-producing products. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001126234-15-000189-index-headers.html	Edgar Link	pending
0001126234-15-000189-index.html	Edgar Link	pending
0001126234-15-000189.txt	Edgar Link	pending
0001126234-15-000189-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
newlinklogorgbwtaga01a01a03.jpg	Edgar Link	pending
nlnk-20150930.xml	Edgar Link	completed
nlnk-20150930.xsd	Edgar Link	pending
nlnk-20150930x10q.htm	Edgar Link	pending
nlnk-20150930xex311.htm	Edgar Link	pending
nlnk-20150930xex312.htm	Edgar Link	pending
nlnk-20150930xex321.htm	Edgar Link	pending
nlnk-20150930_cal.xml	Edgar Link	unprocessable
nlnk-20150930_def.xml	Edgar Link	unprocessable
nlnk-20150930_lab.xml	Edgar Link	unprocessable
nlnk-20150930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2015 Q4 Form 10-Q Financial Statement

#000112623415000189 Filed on November 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2015 Q4 Form 10-Q Financial Statement

#000112623415000189 Filed on November 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo